Literature DB >> 26062900

Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release.

Stephen M Stahl.   

Abstract

Vortioxetine is an antidepressant with multiple pharmacologic modes of action at targets where serotonin neurons connect with other neurons. These actions modify the release of both glutamate and GABA (gamma amino butyric acid) within various brain circuits.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26062900     DOI: 10.1017/S1092852915000334

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  5 in total

1.  Identification of compound-protein interactions through the analysis of gene ontology, KEGG enrichment for proteins and molecular fragments of compounds.

Authors:  Lei Chen; Yu-Hang Zhang; Mingyue Zheng; Tao Huang; Yu-Dong Cai
Journal:  Mol Genet Genomics       Date:  2016-08-16       Impact factor: 3.291

Review 2.  Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse.

Authors:  Tia Sternat; Martin A Katzman
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-25       Impact factor: 2.570

Review 3.  Vortioxetine: Clinical Pharmacokinetics and Drug Interactions.

Authors:  Grace Chen; Astrid-Maria Højer; Johan Areberg; George Nomikos
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

4.  Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.

Authors:  Takeshi Inoue; Shinji Fujimoto; Tatsuro Marumoto; Tadayuki Kitagawa; Kazuyuki Ishida; Tadashi Nakajima; Yoshiya Moriguchi; Keita Fujikawa; Koichiro Watanabe
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-21       Impact factor: 2.570

5.  Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.

Authors:  Michael Cronquist Christensen; Simon Schmidt; Iria Grande
Journal:  J Psychopharmacol       Date:  2022-05-02       Impact factor: 4.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.